Early post-operative brain PET-MRI in glioblastoma surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-site interventional study evaluating the safety and feasibility of performing an early post-operative brain PET-MRI within 48 hours after glioblastoma surgery. The study uses 18F-DOPA with gadolinium-enhanced MRI to explore imaging parameters such as SUVmax, metabolic volume, and tumor-to-striatum ratio for detecting residual tumor tissue. Fifteen adults will be enrolled at CHU Henri Mondor in France and monitored for radiation exposure and adverse events up to 24 hours post-imaging. The trial aims to establish whether this approach can safely provide more accurate post-surgical tumor assessment to guide future patient care. The study duration is 12 months and is categorized as a monocentric, interventional diagnostic investigation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* First resection for a suspected glioblastoma in the past 72h
* Signed informed consent

non-inclusion Criteria:

* Deprived of liberty or under legal protection (e.g, guardianship, trusteeship)
* Patients under 18 years old
* Absence of social security cover
* Pregnancy
* Emergency procedure
* Contraindication to brain MRI, including claustrophobia
* Contraindication to radiotracers or gadolinium injection
* Preoperative cognitive impairment impeding patient information

Exclusion criteria :

* Any postoperative behavioral disorders or medical condition or symptom impeding the completion of brain imaging
* Postoperative medical dependency impeding the patient transfer to the nuclear medicine department (including, but not limited to, invasive ventilation, need for external ventricular drainage…)
* Postoperative histological diagnosis different from glioblastoma

Where it's running

• Hôpital Henri Mondor - Université Paris-Est Créteil (UPEC)
  Créteil, France Recruiting

Study contacts

• Study coordinator: Caroline Apra, MD, PhD
• Email: contact@beams.bio
• Phone: +330149812240

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• YN003 injection in glioma patients

  This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.

  Recruiting at 2 sites Phase 1 Beijing Inno Medicine Co., Ltd. · Los Angeles, California and 4 other locations · NCT07929909

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

• Lixumistat window of opportunity in newly diagnosed glioblastoma

  This study tests whether Lixumistat can benefit adults with newly diagnosed glioblastoma who are planned for surgical tumor removal.

  Recruiting Early Phase 1 University of Miami · Miami, Florida · NCT07884344

• Glioblastoma in Réunion: an epidemiological and socio-anthropological look at patients and care

  A large group of adults with diffuse gliomas in Réunion is being studied to understand how biology, culture, and health care pathways affect diagnosis and treatment.

  Recruiting Centre Hospitalier Universitaire de la Réunion · Saint-Pierre · NCT07865195

• Butterfly glioblastoma: test adding 5-ALA PoMA with LIDU ultrasound to standard care

  This early-phase study tests whether adding 5-ALA–mediated activation with LIDU ultrasound is safe and tolerable for adults with newly diagnosed butterfly glioblastoma, before or during standard chemotherapy and radiotherapy.

  Recruiting Phase 1 Alpheus Medical, Inc. · Buffalo, New York · NCT07862647

• Maintenance radiotherapy after standard glioblastoma treatment

  This study tests whether a single 2 Gy maintenance radiotherapy dose after standard treatment is safe and feasible for adults with newly diagnosed glioblastoma.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07831772

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.